Immune activation by combination human lymphokine-activated killer and dendritic cell therapy

BACKGROUND: Optimal cellular immunotherapy for cancer should ideally harness both the innate and adaptive arms of the immune response. Lymphokine-activated killer cells (LAKs) can trigger early innate killing of tumour targets, whereas long-term adaptive-specific tumour control requires priming of C...

Descripción completa

Detalles Bibliográficos
Autores principales: West, E J, Scott, K J, Jennings, V A, Melcher, A A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171008/
https://www.ncbi.nlm.nih.gov/pubmed/21847125
http://dx.doi.org/10.1038/bjc.2011.290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171008/
https://www.ncbi.nlm.nih.gov/pubmed/21847125
http://dx.doi.org/10.1038/bjc.2011.290

Ejemplares similares